AstraZeneca's fish oil drug fails
Amarin’s Vascepa is the last fish oil-derived drug standing after rivals AstraZeneca and Acasti Pharma suffered separate, significant setbacks on Monday.
As Matt Herper reports, AstraZeneca was forced to stop a large, cardiovascular outcomes clinical trial of Epanova after an independent committee concluded it was “unlikely to demonstrate a benefit to patients.” Separately, a study of Acasti’s fish-oil drug failed to lower triglyceride levels compared to a placebo.
Amarin benefits from its competitors’ misfortunes, but the stock only rose marginally because investors remain concerned about the possibility of generic versions of Vascepa reaching the market. Amarin is suing to stop that from happening, but a decision won’t be known until later this year.
Read more.
As Matt Herper reports, AstraZeneca was forced to stop a large, cardiovascular outcomes clinical trial of Epanova after an independent committee concluded it was “unlikely to demonstrate a benefit to patients.” Separately, a study of Acasti’s fish-oil drug failed to lower triglyceride levels compared to a placebo.
Amarin benefits from its competitors’ misfortunes, but the stock only rose marginally because investors remain concerned about the possibility of generic versions of Vascepa reaching the market. Amarin is suing to stop that from happening, but a decision won’t be known until later this year.
Read more.
No hay comentarios:
Publicar un comentario